Upadacitinib as a rescue therapy for steroid- and infliximab-refractory acute severe ulcerative colitis: short- and long-term effectiveness and safety in a multicenter cohort study
Inflammatory Bowel Diseases · 01.11.2026 · 32 (11) · 2085-2094
DOI: 10.1093/ibd/izag126 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 22.07.2026. Verfasst von Nalan Gülşen Ünal und 24 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Department of Gastroenterology, Ege University, Izmir, 35040, Türkiye. Hauptthemen laut MEDLINE: Infliximab, Colitis, Ulcerative, Heterocyclic Compounds, 3-Ring, Salvage Therapy. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Acute severe active ulcerative colitis (ASUC) often requires rescue therapy when standard medical treatment fails. Data on the use of upadacitinib (UPA) as a rescue option after failure of steroids and infliximab (IFX) and on the long-term outcomes of UPA treatment up to 48 weeks, remain scarce.
Methods
We evaluated hospitalized patients with ASUC (Truelove and Witts criteria) who received UPA following the failure of intravenous corticosteroids (IV-CS) and IFX. Outcomes included UPA persistence, clinical remission (CR), partial Mayo score (pMAYO) ≤ 2, clinical response (≥3-point reduction in pMAYO), and colectomy rates over 48 weeks of follow-up.
Results
Fifty patients with ASUC from 11 centers (male, 54%) received UPA treatment following IV-CS/IFX failure. Prior IFX exposure was 86%, and > 50% of the patients had received ≥ 2 biologics. Continuation was 52% overall (week 4, 90%; week 48, 52%). Discontinuation was due to primary nonresponse (42%), secondary loss of response (46%), or other causes (13%). Adverse events related to UPA occurred in 24% of patients and almost all were nonsevere. Stool frequency, rectal bleeding, pMayo score, and C-reactive protein (CRP) improved rapidly by week 1 and were thereafter maintained to week 48. Colectomy occurred in 22% of patients (nearly half of them in week 1). Week 1 CRs were 60%/30% while the week 48 CR rate was 51%. Higher baseline CRP predicted colectomy; no factor affected UPA persistence.
Conclusion
In this multicenter cohort of patients with ASUC who failed IV-CS and IFX rescue, third-line UPA was associated with a low colectomy rate and sustained response up to 1 year, with an acceptable safety profile. UPA may provide sufficient disease control to prevent or delay colectomy, or to serve as a bridge to alternative therapies. Summary In this retrospective multicenter cohort (11 centers), 50 patients with severe ulcerative colitis refractory to intravenous corticosteroids and infliximab received upadacitinib. Improved symptoms and C-reactive protein (CRP) levels occurred by week 1 and persisted to week 48; colectomy occurred in 22% and adverse events in 24% of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Department of Gastroenterology, Ege University, Izmir, 35040, Türkiye.
- Cerrahpasa Faculty of Medicine, Department of Gastroenterology, Istanbul University-Cerrahpasa, Istanbul, 34098, Türkiye.
- Faculty of Medicine, Department of Gastroenterology, Hacettepe University, Ankara, 06230, Türkiye.
- Faculty of Medicine, Department of Gastroenterology, Marmara University, Istanbul, 34899, Türkiye.
- Faculty of Medicine, Department of Gastroenterology, Akdeniz University, Antalya, 07070, Türkiye.
- Faculty of Medicine, Department of Gastroenterology, Istanbul University, Istanbul, 34093, Türkiye.
ORCID-Profile: Oğuz Kağan Bakkaloğlu
Zitieren
APA
Ünal, N. G., Bakkaloğlu, O. K., Kav, T., Eşkazan, T., Kani, H. T., Akpınar, A., Akıncıoğlu, P., Dağcı, G., Şendur, İ., Büyüktorun, İ., Barutçu, S., Kılıç, G., Bengi, G., Çavuş, B., Oruç, N., Alahdab, Y. Ö., Atuğ, Ö., Dinçer, D., Karakan, T., …, & Çelik, A. F. (2026). Upadacitinib as a rescue therapy for steroid- and infliximab-refractory acute severe ulcerative colitis: short- and long-term effectiveness and safety in a multicenter cohort study. Inflammatory Bowel Diseases, 32(11), 2085-2094. https://doi.org/10.1093/ibd/izag126
Vancouver
Ünal NG, Bakkaloğlu OK, Kav T, Eşkazan T, Kani HT, Akpınar A, et al. Upadacitinib as a rescue therapy for steroid- and infliximab-refractory acute severe ulcerative colitis: short- and long-term effectiveness and safety in a multicenter cohort study. Inflammatory Bowel Diseases. 2026;32(11):2085-2094. doi:10.1093/ibd/izag126
BibTeX
@article{nal2026,
author = {Ünal, Nalan Gülşen and Bakkaloğlu, Oğuz Kağan and Kav, Taylan and Eşkazan, Tuğçe and Kani, Haluk Tarık and Akpınar, Atilla and Akıncıoğlu, Pırıl and Dağcı, Gizem and Şendur, İbrahim and Büyüktorun, İlker and Barutçu, Sezgin and Kılıç, Güner and Bengi, Göksel and Çavuş, Bilger and Oruç, Nevin and Alahdab, Yeşim Özen and Atuğ, Özlen and Dinçer, Dinç and Karakan, Tarkan and Hatemi, Ali İbrahim and Erzin, Yusuf Ziya and Tezel, Ahmet and Törüner, Murat and Akyüz, Filiz and Çelik, Aykut Ferhat},
title = {Upadacitinib as a rescue therapy for steroid- and infliximab-refractory acute severe ulcerative colitis: short- and long-term effectiveness and safety in a multicenter cohort study},
journal = {Inflammatory Bowel Diseases},
year = {2026},
volume = {32},
number = {11},
pages = {2085--2094},
doi = {10.1093/ibd/izag126}
}
EUVIMED